ASX:MXC Argent BioPharma (MXC) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free MXC Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.16 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield3.70%Price TargetN/A Stock AnalysisStock Analysis Get Argent BioPharma alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About Argent BioPharma Stock (ASX:MXC)MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.Read More Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy MXC Stock News HeadlinesApril 1, 2024 | msn.comMGC Pharmaceuticals rebrands as Argent BioPharma in strategic transformationFebruary 13, 2024 | finanznachrichten.deMGC Pharmaceuticals Ltd: MGC Pharma Rebrands as Argent BioPharma in Strategic TransformationApril 26, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. February 13, 2024 | finance.yahoo.comMGC Pharma Rebrands as Argent BioPharma in Strategic TransformationFebruary 3, 2024 | afr.comMGC Pharmaceuticals LtdFebruary 2, 2024 | proactiveinvestors.com.auMGC Pharma delighted with position after resetDecember 15, 2023 | benzinga.comMGC Pharmaceuticals Ltd Stock (OTC:MGCLF), Analyst Ratings, Price Targets, PredictionsDecember 15, 2023 | benzinga.comMGC Pharmaceuticals Stock (OTC:MGCLF) Dividends: History, Yield and DatesApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.November 30, 2023 | proactiveinvestors.comMGC Pharmaceuticals reshuffles board and appoints joint UK brokerNovember 15, 2023 | uk.investing.comMGC Pharmaceuticals Ltd (MXCDA)November 13, 2023 | proactiveinvestors.comMGC Pharmaceuticals reveals strategic objectives for H1 2024August 31, 2023 | au.investing.comMGC Pharmaceuticals hails pivot to medical products, legacy sales hitAugust 29, 2023 | au.investing.comMGC Pharmaceuticals closes SPP with funds to go toward production of cannabinoid medicinesAugust 14, 2023 | proactiveinvestors.comMGC Pharmaceuticals to "move forward and speak to the FDA"August 14, 2023 | msn.comMGC Pharma hits another milestone in path to FDA approval for anti-inflammatory CimetraAAugust 1, 2023 | proactiveinvestors.comMGC Pharmaceuticals proposes fundraising for Australian investorsAugust 1, 2023 | proactiveinvestors.comMGC Pharmaceuticals receives permission to import psilocybin mushrooms into...August 1, 2023 | proactiveinvestors.com.auMGC Pharmaceuticals gets first psilocybin import green light import for research facilityAugust 1, 2023 | finance.yahoo.comMGC Pharmaceuticals receives permission to import psilocybin mushrooms into EuropeJuly 31, 2023 | msn.comMGC Pharma nabs import approval for psilocybin to Slovenian research facilityJuly 30, 2023 | au.investing.comMGC Pharmaceuticals gets green light for first import of psilocybin to research facilityJuly 14, 2023 | marketwatch.comMGC Pharmaceuticals Raises GBP650,000 via Heavily Discounted Placing, SubscriptionJuly 14, 2023 | proactiveinvestors.comMGC Pharmaceuticals raises £0.7mln for working capitalJuly 13, 2023 | proactiveinvestors.comMGC Pharmaceuticals raises A$1.335 million for working capitalJuly 12, 2023 | au.investing.comMGC Pharmaceuticals clarifies shape of recent AMC Pharma orderJuly 7, 2023 | proactiveinvestors.com.auMGC Pharmaceuticals "pushing on" after signing fresh $1mln orderSee More Headlines Receive MXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2019Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolASX:MXC CUSIPN/A CIKN/A Webwww.mgcpharma.com.au Phone61 8 6382 3390FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-307.40% Return on Assets-58.96% Debt Debt-to-Equity Ratio1,436.12 Current Ratio0.75 Quick Ratio0.50 Sales & Book Value Annual Sales$1.32 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow25.00 Book ValueA$0.04 per share Price / BookN/AMiscellaneous Outstanding Shares43,850,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.03 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Roby Reuven Zomer (Age 44)Co-Founder, CEO, MD & Executive Director Comp: $354.02kMr. Tom CairnsChief Accounting OfficerMs. Yifat SteuerDeputy CEO & COOMs. Nicole Ann GodresseGlobal Chief Sales OfficerMr. Amir PolakChief Pharmaceutical Development OfficerMs. Sabina SuljakovicHead of the Quality Assurance DepartmentDr. Nadya LisovoderChief Medical OfficerMs. Sasha FriedmanDeputy CEOYair TalChief Information Security OfficerMr. Robert ClementsChief Commercial OfficerMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All CompetitorsInsidersRoss WalkerSold 1,050,000 sharesTotal: $9,450.00 ($0.01/share) MXC Stock Analysis - Frequently Asked Questions How were Argent BioPharma's earnings last quarter? Argent BioPharma Limited (ASX:MXC) released its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter. What other stocks do shareholders of Argent BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Argent BioPharma investors own include Triton Minerals (TON), Rox Resources (RXL), Northern Minerals (NTU), Medlab Clinical (MDC), Laneway Resources (LNY), iSignthis (ISX), Intel (INTC), Bod Australia (BDA), Azure Minerals (AZS) and AusCann Group (AC8). This page (ASX:MXC) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argent BioPharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
